Published Date: 29 Oct 2025
Mayo Clinic researchers have discovered a key reason why certain breast cancers might not respond to an important new class of therapeutics called antibody drug conjugates (ADCs). These treatments pair an antibody that targets ...
Read Full NewsClinicians continue prescribing antibiotics unnecessarily despite growing evidence supporting shorter, targeted, and reassessed treatment strategies.
Nearly 300 experts warn that rising vaccine misinformation is reversing gains — measles and meningococcal infections are resurging while France updates the 2026 schedule.
Patients were randomly assigned 1:1 to receive either concurrent radiation dose escalation to the lumpectomy cavity during whole-breast irradiation or sequential boost after whole-breast irradiation.
The agency OK’d trastuzumab deruxtecan for two indications in HER2-positive early-stage breast cancer, covering both the neoadjuvant and adjuvant settings.
1.
Kate Middleton Reaches Cancer Treatment Milestone
2.
Lesser-known lobular breast cancer on the rise in U.S. women
3.
Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?
4.
When Healthcare Chatbots Fall Short of Human Connection
5.
Discovery of breast cancer treatment resistance mechanism could lead to new hope for some
1.
Oncolytic Viruses in Breast Cancer: Unlocking Synergy with Novel Combination Therapies
2.
Skin-Sparing Mastectomy: Balancing Cancer Control with Cosmetic Results
3.
Malignant Prolactinoma: Prolactin Surge with Minimal Growth Masks Widespread Metastases
4.
The Journey Beyond Treatment: Empowering Cancer Survivorship with Technology and Artificial Intelligence
5.
The Importance of Balanced Potassium Levels in Maintaining Good Health
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
2.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
3.
Updates on Standard V/S High Risk Myeloma Treatment
4.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
5.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation